The benefit of induction chemotherapy in patients age > or = 75 years

Cancer
Norbert VeyDominique Maraninchi

Abstract

Patients age > or = 75 years with acute myeloid leukemia (AML) generally are offered palliative treatments instead of induction chemotherapy. The authors conducted a retrospective study comparing the outcomes among these elderly patients with the outcomes among younger patients to assess the impact of intensive treatment approaches in this age group. One hundred ten consecutive patients age > or = 75 years with newly diagnosed AML (excluding patients with acute promyelocytic leukemia) were treated in the authors' center over 10 years. Initial treatment was comprised of anthracycline-based induction chemotherapy (i.e., intravenous idarubicin or daunorubicin for 3 days plus cytarabine [ARAC] for 7 days [3 + 7 regimen] or oral idarubicin) for 62 patients (56%), antimetabolite-based chemotherapy (including low-dose ARAC, oral 6-mercaptopurine plus methotrexate, or hydroxyurea) for 40 patients (36%), and supportive care only for 8 patients (7%). Results were compared with the results from 200 patients ages 65-74 years who were treated during the same period. A complete response (CR) to anthracycline-based induction therapy was achieved by 23 of 62 patients (37%), and the 2-year overall survival rate was 22% (which was not statistica...Continue Reading

References

Sep 1, 1992·British Journal of Haematology·J ReiffersP Hurteloup
May 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonM J Keating
Aug 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M J KeatingE J Freireich
Jan 1, 1994·British Journal of Haematology·M BaudardR Zittoun
Apr 29, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M ExtermannL Balducci
Feb 19, 2000·Hematology/oncology Clinics of North America·L Balducci, M Extermann
Feb 19, 2000·Hematology/oncology Clinics of North America·M Extermann, M Aapro
Aug 14, 2001·Critical Reviews in Oncology/hematology·A PintoF Ferrara
Jan 16, 2002·Current Opinion in Genetics & Development·Charles L Sawyers
Dec 1, 1961·Journal of Chronic Diseases·E J FREIREICHE FREI

❮ Previous
Next ❯

Citations

Mar 22, 2006·Diseases of the Colon and Rectum·Rebecca P BrosensAlexander F Engel
Aug 2, 2013·Future Oncology·Courtney D DiNardoFarhad Ravandi
Nov 19, 2010·Expert Review of Hematology·Yesid AlvaradoFrancis J Giles
Mar 1, 2006·Expert Review of Anticancer Therapy·Norbert Vey, Frank Giles
Jan 1, 2011·Journal of Geriatric Oncology·Heidi D KlepinShannon L Mihalko
Jul 20, 2006·British Journal of Haematology·Jonathan E Kolitz
Feb 6, 2008·American Journal of Hematology·Kebede HusseinDaniel Weisdorf
Feb 10, 2011·Geriatrics & Gerontology International·Shine AbeToshihiko Iwamoto
Oct 19, 2012·American Journal of Hematology·Inho KimUNKNOWN Korean Society of Hematology AML/MDS working party
Nov 13, 2007·Critical Reviews in Oncology/hematology·Felicetto FerraraFranco Leoni
Jul 15, 2005·Seminars in Hematology·Michael Lübbert, Mark Minden
Feb 19, 2010·Expert Opinion on Pharmacotherapy·Norbert Vey, Frank Giles
Feb 25, 2015·Leukemia Research Reports·Srivasavi Dukka, David T Bowen
Jul 10, 2014·Leukemia·R B Walter, E H Estey
Sep 2, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas PrébetUNKNOWN Core Binding Factor Acute Myeloid Leukemia (CBF AML) intergroup
Mar 14, 2009·The Oncologist·Heidi D Klepin, Lodovico Balducci
May 16, 2018·International Journal of Molecular Sciences·Jianjian ZhuangHongdong Li
Aug 9, 2019·Applied Health Economics and Health Policy·Gabriel TremblayJosée Hébert
Dec 29, 2020·American Journal of Hematology·Jorge E Cortes, Priyanka Mehta
Jun 16, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C-C ChenJ-P Gau

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.